CHOP DC

CHOP DC

A “first-generation” combination chemotherapy regimen used for low- and intermediate-grade non-Hodgkin lymphomas (NHLs). Despite extensive clinical research, CHOP is considered better than some 2nd- and 3rd-generation chemotherapy regimens (e.g., m-BACOD, MACOP-B and ProMACE-CytaBOM) for treating NHL: while overall survival with all is the same, fatal toxic reactions occur in 1% of CHOP patients compared to 3–6% of those treated with other protocols.